Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

229
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
229
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Cancer Vaccines01:30

Cancer Vaccines

946
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
946

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EGFR inhibition down-regulates MGMT and enhances responsiveness to temozolomide in glioblastoma.

Science translational medicine·2026
Same author

Olvi-Vec oncolytic immunotherapy and reversal of platinum resistance in ovarian cancer.

Gynecologic oncology reports·2026
Same author

Anti-Hu-Associated Paraneoplastic Myeloneuropathy as the Initial Presentation of Early-Onset Colon Adenocarcinoma.

ACG case reports journal·2026
Same author

Outcomes of Endoscopic Single-Gated Compared to Multigated Approach using Lumen Apposing Metal Stents in the Management of Necrotizing Pancreatitis.

Endoscopy international open·2026
Same author

Indirect comparison of endoscopic balloon dilatation, stent placement, and stricturotomy for lower gastrointestinal strictures in Crohn's disease: a systematic review and meta-analysis.

European journal of gastroenterology & hepatology·2026
Same author

QSPR modeling and multi-criteria ranking of antiviral drugs using degree-based topological indices, artificial neural networks, and TOPSIS.

Computational biology and chemistry·2026

Related Experiment Video

Updated: Jan 13, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.7K

Biosimilars in Gynecologic Cancers: Basic Principles and New Horizons.

Mariem Galuia1, Azhar Hussain2, Sarfraz Ahmad3

  • 1Department of Internal Medicine, AdventHealth Hospital, Orlando, FL 32804, USA.

Frontiers in Bioscience (Elite Edition)
|January 8, 2026
PubMed
Summary

Biosimilars offer a cost-effective alternative to biological therapies for gynecological cancers, demonstrating comparable efficacy and safety to reference biologics. These treatments improve patient outcomes and reduce financial burdens.

Keywords:
biosimilarscervical cancercost-effectivenessendometrial cancergynecologic cancersmonoclonal antibodiesovarian cancertargeted therapies

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.7K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.6K

Related Experiment Videos

Last Updated: Jan 13, 2026

Stereotactic Radiosurgery for Gynecologic Cancer
10:35

Stereotactic Radiosurgery for Gynecologic Cancer

Published on: April 17, 2012

18.7K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

3.7K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.6K

Area of Science:

  • Oncology
  • Pharmacoeconomics
  • Drug Development

Background:

  • Biological therapies have revolutionized cancer treatment but face challenges with cost and accessibility.
  • The need for affordable and accessible cancer treatments is critical, especially after recent supply chain disruptions.
  • Biosimilars present a promising solution by offering highly similar alternatives to existing biologics.

Purpose of the Study:

  • To review the role and impact of biosimilars in treating gynecological cancers.
  • To compare the efficacy, safety, and cost-effectiveness of biosimilars against reference biologics.
  • To identify barriers hindering the widespread adoption of biosimilars in oncology.

Main Methods:

  • A comprehensive literature review of studies, regulatory guidelines, and data on biosimilars for gynecological cancers.
  • Analysis of pivotal clinical trials (e.g., GOG-0218, ICON7, RUBY) for efficacy and safety assessment.
  • Examination of key oncologic therapies like bevacizumab, trastuzumab, and pembrolizumab biosimilars.

Main Results:

  • Biosimilars exhibit comparable efficacy and safety profiles to their reference biologic counterparts.
  • Evidence suggests biosimilars are more cost-effective, reducing the financial burden on patients and healthcare systems.
  • Clinical trials indicate biosimilars contribute to disease control and improved overall survival.

Conclusions:

  • Biosimilars are a viable and valuable option for gynecological cancer treatment, offering comparable outcomes at a lower cost.
  • Addressing challenges such as immunogenicity, interchangeability, and clinician awareness is crucial for broader uptake.
  • Increased utilization of biosimilars can enhance treatment accessibility and affordability in oncology.